Which is Better for RA, Methotrexate or Hydroxychloroquine? What the Evidence Says

Methotrexate is the better choice for most people with rheumatoid arthritis. Major rheumatology bodies including the ACR and EULAR both recommend it as the first DMARD to try, and the evidence backs that up. In clinical trials, methotrexate as a single drug brings around 25 to 35 percent of patients into remission after about a year. Hydroxychloroquine is gentler on the body, but it only reaches remission in roughly 10 to 20 percent of patients on its own. For moderate to severe RA, that gap matters.

That said, hydroxychloroquine has a real role. For very mild RA, certain medical conditions, or as part of a combination approach, it earns its place. The right answer depends on disease severity, your health history, and what you and your doctor decide together.

What is the Difference Between Methotrexate and Hydroxychloroquine for RA?

Both drugs are DMARDs, which means they modify the disease itself rather than just masking pain. But they work through completely different mechanisms and sit at different points on the potency scale.

Methotrexate blocks enzymes involved in folate metabolism and suppresses several inflammatory signaling pathways. The result is a meaningful reduction in joint swelling, pain, and structural damage. It's become the most successful treatment for rheumatoid arthritis run in the last two decades. When researchers want to test a new biologic or JAK inhibitor, they almost always add it on top of methotrexate because methotrexate alone sets a high bar.

Hydroxychloroquine, originally developed as an antimalarial, works more gently. It interferes with how immune cells process signals inside their lysosomes, which dials down certain inflammatory responses. The effect is real but modest. It doesn't stop joint erosion the way methotrexate does, and it takes longer to show results.

The clearest way to frame the difference: methotrexate is a disease-suppressing drug. Hydroxychloroquine is a disease-moderating one.

Which Drug Works Faster for Rheumatoid Arthritis?

Neither drug is fast by everyday standards, but methotrexate shows measurable effects sooner. Most patients notice some improvement within six to eight weeks of starting methotrexate, with fuller effects appearing around three to six months. Hydroxychloroquine typically takes three to six months before patients feel a meaningful difference, sometimes longer.

In the SELECT-EARLY trial, patients on methotrexate monotherapy showed sustained clinical improvement through 48 weeks, with 82 percent completing the initial treatment period. That kind of retention in a trial usually reflects both tolerability and perceived benefit, which matters when you're trying to judge real-world speed of response.

The speed question often gets conflated with tolerability. Hydroxychloroquine feels easier to start because the side effects are milder, so patients sometimes assume it's working when they're simply not suffering. Methotrexate can cause nausea and fatigue early on, which makes the first few weeks harder even when the drug is doing its job.

Can Methotrexate and Hydroxychloroquine Be Taken Together for RA?

Yes, and this combination is well established in rheumatology practice. The triple therapy regimen of methotrexate, hydroxychloroquine, and sulfasalazine has been used for decades and remains a recommended option in ACR guidelines, particularly when cost or access to biologics is a factor.

The logic behind combining them is sound. Hydroxychloroquine may reduce methotrexate toxicity slightly while adding its own anti-inflammatory effect through a different pathway. The two drugs don't compete with each other mechanically, and the combination has a reasonable safety record in long-term use.

Head-to-head data comparing the combination against methotrexate alone is thinner than you'd hope. Most modern trials use methotrexate as the anchor and test biologics or JAK inhibitors on top of it. But the triple DMARD combination remains a legitimate strategy, especially for patients who can't access or afford biologic therapy. Explore newer treatment options beyond traditional DMARDs for additional context.

What Are the Side Effects of Methotrexate Compared to Hydroxychloroquine?

This is where hydroxychloroquine has a genuine advantage. Its safety comparison across almost every category.

Methotrexate's most common side effects are nausea, mouth sores, fatigue, and elevated liver enzymes. Most of these can be managed by taking folic acid alongside it, which is now standard practice. Serious liver toxicity is rare with modern monitoring, but it does require regular blood tests. Lung toxicity is uncommon but serious when it occurs. The NORD-STAR trial found that methotrexate combined with tocilizumab produced more adverse events than methotrexate with conventional therapy (HR 1.48, 95% CI 1.20 to 1.84), which gives some sense of how methotrexate interacts with other immunosuppressants.

Hydroxychloroquine's main concern is retinal toxicity with long-term use. At standard doses (under 5 mg per kg of body weight per day), the risk is low in the first five years but rises with cumulative exposure. Annual eye exams are recommended after five years of use. Stomach upset is possible but usually mild. It doesn't require the same level of blood monitoring as methotrexate.

For patients with liver disease, heavy alcohol use, or significant kidney impairment, hydroxychloroquine is the safer option by a wide margin. For everyone else, methotrexate's side effects are manageable with proper monitoring and folic acid supplementation.

Is Hydroxychloroquine Effective Enough to Treat Rheumatoid Arthritis on Its Own?

For mild RA with no joint erosion and low disease activity, hydroxychloroquine monotherapy can be enough. Some patients with early, seronegative RA (negative for rheumatoid factor and anti-CCP antibodies) do well on it alone.

For moderate to severe RA, the honest answer is no. Hydroxychloroquine doesn't prevent joint damage reliably on its own. It reduces symptoms and may slow progression, but it doesn't match methotrexate's ability to halt structural deterioration. If you have elevated inflammatory markers, positive antibodies, or visible erosions on imaging, hydroxychloroquine alone is unlikely to be enough.

Clinical consensus suggests hydroxychloroquine monotherapy is appropriate in three situations: very mild disease with no damage risk factors, patients who can't tolerate or are contraindicated for methotrexate, or as a bridge while waiting to start a stronger regimen.

Which is Safer for Long-Term Use in RA?

Long-term safety data for both drugs is extensive, which is reassuring. The five-year data from SELECT-EARLY showed methotrexate monotherapy maintained a manageable safety profile over that period, though some patients needed treatment escalation when the drug alone wasn't sufficient.

Hydroxychloroquine's long-term risk is primarily the retinal toxicity mentioned above. With annual screening after five years, serious vision loss is rare but not zero. Methotrexate's long-term risks center on liver and lung, both of which are monitored through routine blood work and clinical review.

What most articles miss is that the safety comparison shifts depending on what you're comparing against. Methotrexate used as a monotherapy at 15 to 25 mg weekly with folic acid and regular monitoring is quite safe over years. The risk profile looks worse when methotrexate is combined with biologics or other immunosuppressants, which is where the NORD-STAR data becomes relevant. Hydroxychloroquine's safety advantage is most meaningful for patients who can't tolerate immunosuppression or who have comorbidities that make liver or lung monitoring difficult.

Three Things Most Articles Get Wrong About This Comparison

First, most comparisons treat this as a binary choice when combination therapy is often the real answer. The question isn't always methotrexate or hydroxychloroquine. For many patients, it's methotrexate alone versus methotrexate plus hydroxychloroquine versus methotrexate plus a biologic. Framing it as a head-to-head misses how rheumatologists actually think about treatment.

Second, the remission rate numbers get misused. When you read that methotrexate achieves remission in 25 to 35 percent of patients, that sounds low. But remission in RA is a strict clinical definition. Low disease activity, which is the more common outcome and still represents meaningful improvement, occurs in a much higher proportion of patients. Hydroxychloroquine's numbers look even lower by comparison, but the gap in real-world functional improvement is what matters most to patients.

Third, exercise and physical activity in drug comparison articles. People with RA who engage in structured physical activity alongside their DMARD therapy consistently report better outcomes than those who rely on medication alone. A supervised exercise program, including resistance training adapted for joint protection, improves pain, fatigue, and physical function in ways that neither methotrexate nor hydroxychloroquine can replicate on their own. For people in Melbourne managing RA, working with an NDIS personal trainer who understands inflammatory arthritis can be a meaningful part of the overall treatment picture alongside whatever DMARD your rheumatologist prescribes.

When Should You Choose Hydroxychloroquine Over Methotrexate?

There are clear situations where hydroxychloroquine is the right first choice.

• Significant liver disease or cirrhosis, where methotrexate's hepatotoxicity risk is unacceptable
• Heavy alcohol use that can't be stopped, for the same reason
• Severe kidney impairment that affects methotrexate clearance
• Planning pregnancy in the near term (both drugs require stopping, but the planning window differs)
• Very mild, early RA with no erosions and low antibody levels
• Patient preference for a lower-monitoring regimen when disease activity is genuinely low

Outside these situations, methotrexate is the evidence-based first choice. That's not a close call in the current literature.

FAQ

Can I switch from hydroxychloroquine to methotrexate if it stops working?

Yes. This is a common clinical pathway. If hydroxychloroquine isn't controlling your RA adequately, your rheumatologist will typically add or switch to methotrexate. Switching is straightforward and doesn't require a washout period.

Does methotrexate require folic acid?

Yes. Folic acid at 1 to 5 mg daily is standard practice alongside methotrexate. It reduces the risk of mouth sores, nausea, and some liver effects without meaningfully reducing the drug's effectiveness against RA.

How long do I need to take these drugs?

RA is a chronic condition, and long-term treatments. Most patients stay on their DMARD regimen indefinitely, with dose adjustments based on disease activity. Stopping treatment usually leads to disease flare.

Is methotrexate a chemotherapy drug?

Methotrexate is used in chemotherapy at much higher doses than those used for RA. The doses used in rheumatology (typically 15 to 25 mg once weekly) are far lower than cancer doses and work through a different mechanism at that range. The chemotherapy association causes unnecessary anxiety for many RA patients.

Can hydroxychloroquine cause eye damage?

Yes, but the risk is low at standard doses in the first five years of use. Annual eye exams with an ophthalmologist are recommended after five years of continuous use. Stopping the drug if early retinal changes are detected prevents serious vision loss.

Which drug is better if I also have lupus?

Hydroxychloroquine is a cornerstone treatment for lupus and is often continued even when methotrexate is added for RA. If you have overlap syndrome or features of both conditions, your rheumatologist may recommend both drugs together.

The One Thing to Take Away

If you have moderate to severe RA and no contraindications, start methotrexate. Take folic acid with it, get your blood work done on schedule, and give it at least three to six months before judging whether it's working. Hydroxychloroquine is a useful drug in the right situation, but it's not a substitute for methotrexate when your joints are at risk of damage. Ask your rheumatologist specifically about your disease activity score and whether your current treatment is actually protecting your joints, not just reducing your symptoms.

About the author

John Carter

Undergraduate degree in mathematics/statistics from the University of Melbourne. PhD in Statistics from Harvard University

I'm a quantitative scientist with a deep passion for improving health outcomes through rigorous statistical methods and data-driven decision-making.

Connect on LinkedIn →